EXPRESSION OF miRNA-126, -205 AND -214 IN BENIGN AND MALIGNANT NEOPLASMS OF THE PROSTATE GLAND: POSSIBLE DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-3-2019-g.7695Keywords:
benign prostatic hyperplasia, blood serum, miRNA, prostate cancer, tumor tissueAbstract
The need for early diagnosis of prostate cancer (PCa) and the choice of optimal treatment tactics encourage the search and introduction of new, more sensitive, specific and effective diagnostic and predictive markers into the clinical practice. The most promising in this direction is the use of miRNAs. It has been shown that they have a significant advantage over other biomarkers due to their stability, since miRNA profile changes in the early stages of carcinogenesis. Aim: to investigate the level of miRNA-126, -205 and -214 expression in blood serum and tumor tissue from patients with benign and malignant neoplasms of the prostate and evaluate the possibility of their use as diagnostic and prognostic markers. Object and methods: The research was conducted on the clinical material of 70 patients with stage II and III PCa and 20 patients with benign prostatic hyperplasia (BPH). The control of the miRNAs in the peripheral blood of 20 healthy donors served as control. Expression of miRNA-126, -205 and -214 in blood serum and tumor tissue was determined by RT-PCR. Results: the development of neoplasms in the prostate gland has been shown to be accompanied by a change in the expression of miRNA-126 and miRNA-205 and -214 both in tumor and in blood serum. We observed a decrease in the miRNA-126 levels is serum from PCa and BPH patients, at the same time, the levels of miRNA-214 and -205 were increased in comparison with healthy donors. The levels of all investigated miRNAs were higher in tissue of PCa when compared with BPH samples. We established a link between the expression of the investigated miRNAs in serum and tumor tissue with such clinical and pathological characteristics of PC as age, cancer stage, presence of metastases in regional lymph nodes, Glison score and PSA level. Conclusion: the obtained results indicate the connection of miRNA-126, -205 and -214 expression in blood serum and tumor tissue with the main clinical and pathological characteristics of patients with PCa. This evidence proves the involvement of these miRNAs in the development of the malignancy degree of PCa, and substantiates the need to continue the study of the proposed miRNAs panel for their use as additional prognostic and diagnostic markers.
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Cancer in Ukraine, 2016–2017. Incidence, mortality, activities of oncological service. Bull Natl Cancer Registry of Ukr. Kyiv 2018; 19: 136 p. (in Ukrainian).
Scherbina OV, Sakalo VS, Kovalyov MP, et al. Diagnostics and monitoring of prostatic cancer. Oncology 2006; 8 (4): 322–6 (in Ukrainian).
Alyaev YuG, Bezrukov YeA, Shestiperov PA. Molecular pathology of prostate cancer: diagnostic and prognostic value of major markers. Cancer Urology 2006; 2: 45–51 (in Russian).
Strigina EA, Medvedev VL, Kurzanov AN. Diagnostic and prognostic markers in prostate cancer. Modern Problems of Science and Education 2016; 2: 14–23 (in Russian).
Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 2010; 10 (5): 543–50.
Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumorsuppressor microRNAs in cancer. Oncogene 2012; 31: 1609–22.
Litvinova NYu, Dubenko DE, Eliseeva AM, et al. MicroRNA-126: a new perspective direction in the diagnosis and treatment of ischemic limb diseases. UMJ Heart & Vessels 2016; 3: 91–4 (in Ukrainian).
Luu HN, Lin HY, Sørensen KD, et al. miRNAs associated with prostate cancer risk and progression. BMC Urology 2017; 17 (1): 18.
Penna E, Orso F, Taverna D. miR-214 as a key hub that controls cancer networks: small player, multiple functions. J Invest Dermatol 2015; 135 (4): 960–9.
Zadvornyi TV, Lukianova NY, Borikun TV, et al. Effects of exogenous lactoferrin on phenotypic profile and invasiveness of human prostate cancer cells (DU145 and LNCaP) in vitro. Exp Oncol 2018; 40 (3): 184–9.
Stroy А. Micro ribonucleic acids in oncourology: perspectives of usage. ECPB 2015; 1: 56–62 (in Ukrainian).
Watahiki A, Wang Y, Morris J, et al. MicroRNAs associated with metastatic prostate cancer. PloS One 2011; 6 (9): e24950.
Al‑Kafaji G, Said HM, Alam MA, et al. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification. Oncol Lett 2018; 16 (1): 1357–65.
Yang Q, Sun P, Feng H, et al. Reduced expression level of miR-205 predicts poor prognosis in osteosarcoma. Biomed Res 2018; 28 (21): 9248–52.
Fitzgerald KA, Guo J, Tierney EG, et al. The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics. Biomaterials 2015; 66: 53–66.
Kalogirou C, Spahn M, Krebs M, et al. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci 2013; 14 (11): 21414–34.
Boll K, Reiche K, Kasack K, et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013; 32 (3): 277.
Sun T, McKay R, Kantoff Р, et al. The role of miRNAs in prostate cancer. Eur Urol 2015; 68 (4): 589–90.
Walter BA, Valera VA, Pinto PA, et al. Comprehensive microRNA profiling of prostate cancer. J Cancer 2013; 4 (5): 350–7.
Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int 2013; 1 (1): 3–9.
